Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Trial statusNot yet recruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexAll

Age40+

SponsorJason Ahee, M.D.

About this trial

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

visually significant cataracts

allergy to fluoroquinolones, cobalamin (B12)

60,000 Participants

are divided into 2 treatment groups

Jason Ahee, M.D.

Lead sponsor

Zion Therapeutics, LLC

Sponsor institution